Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Meet Scorpion, the latest, Nvidia-powered service robot from Richtech Robotics which crafts personalized cocktails and wine selections based on your mood
Gina Heeb, finance reporter at The Wall Street Journal, joins us to discuss the current state of the real estate market and when things may turn around. Watch!
Managing Editor at Tom's Guide, Kate Kozuch, joins Cheddar to explain how Apple's AirPods now work as hearing aids and what she thinks of Apple Intelligence.
Co-founder and CEO of Rad Intel, Jeremy Barnett, joins Cheddar anchor Dave Briggs to discuss the influencer marketing space and how RAD is changing the game.
